JPRN-jRCT1041190083RecruitingPhase 2
Phase II study of ramucirumab for the patients with advanced hepatocellular carcinoma previously treated with lenvatinib
Yamashita Tatsuya0 sites33 target enrollmentStarted: November 21, 2019Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Enrollment
- 33
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 20age old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- •clinically diagnosed as hepatocellular carcinoma; unsuitable for local therapy; AFP>=400ng/mL; good liver functional reserve; 20 years old or older, ECOG Performance status <=2; preservation of major organ function; written informed consent
Exclusion Criteria
- •refractory ascites or pleural effusion; risky varices; double cancer; metastases to central nervous system; unstable angina or myocardial infarction; severe complication; active infection; pregnant or lactating women and her partner, or women of childbearing potential; mental disorder; other factors unsuitable for participant
Investigators
Similar Trials
Unknown
Phase 2
A Phase 2 Study of Ramucirumab in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First Line Platinum- or Fluoropyrimidine-Containing Combination Therapy in Japanese PatientsGastric CancerJPRN-jRCT2080222292Eli Lilly Japan K.K.
Active, not recruiting
Phase 2
Phase II study of ramucirumab in combination with erlotinib for untreated EGFR mutation-positive non-squamous non-small cell lung cancer patients with pleural effusion: RELAY-EffusioEGFR mutation positive advanced non-small cell lung cancerJPRN-jRCTs051210138Kaneda Hiroyasu40
Unknown
Phase 1
Phase 1b Study of Ramucirumab in Combination With Fluoropyrimidines and Platinum-Based Agents in Japanese Patients With Metastatic Gastric/Gastroesophageal Junction AdenocarcinomaStomach NeoplasmsJPRN-jRCT2080222764Eli Lilly Japan K.K.
Completed
Not Applicable
Phase II study of rituximab in patients with severe systemic lupus erythematosusSystemic lupus erythematosusJPRN-UMIN000000763Zenyaku Kogyo Co., Ltd.30
Completed
Not Applicable
A Phase II study of Ramucirumab beyond disease progression in combination with Irinotecan after failure of weekly Paclitaxel plus Ramucirumab in advanced gastric cancer patients previously treated with fluoropyrimidine and platinumGastric cancerJPRN-UMIN000022956The University of Tokyo53